A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
Status:
Terminated
Trial end date:
2017-06-05
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter study that will be conducted at up to 40 centers in the
United States and Outside United States (OUS). Participants in the study will be randomly
assigned to receive either ONCO-DOX or sorafenib treatment. This study will evaluate the
study participants' outcomes (medical condition) after being treated with ONCO-DOX and
compare it to those treated with sorafenib alone.